论文部分内容阅读
目的观察孟鲁司特钠联合布地奈德治疗支气管哮喘临床疗效。方法 74例支气管哮喘患者,随机分为对照组和研究组,各37例。对照组采用孟鲁司特吸入治疗,研究组在此基础上增加布地奈德口服治疗,对比两组的临床疗效。结果研究组治疗总有效率89.19%显著高于对照组的67.57%(P<0.05);治疗后研究组的一秒钟用力呼气容积和最大呼气流量的昼夜波动率分别为(92.51±3.10)%和(91.20±2.17)%,明显优于对照组的(82.61±2.07)%和(85.36±2.43)%(P<0.05)。研究组的不良反应发生率5.41%少于对照组的24.32%(P<0.05)。结论孟鲁司特钠联合布地奈德治疗支气管哮喘可获得较为理想的临床疗效,不仅能够对患者的肺功能起到良好的改善作用,而且使用安全性较高,无明显不良反应情况,值得推广。
Objective To observe the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods 74 patients with bronchial asthma were randomly divided into control group and study group, 37 cases in each group. The control group was treated with montelukast inhalation, and the research group increased budesonide oral treatment on the basis of this study, and compared the clinical curative effect of the two groups. Results The total effective rate of the study group was 89.19%, which was significantly higher than that of the control group (67.57%, P <0.05). The daytime and night fluctuation of the forced expiratory volume and the maximum expiratory flow in the study group were (92.51 ± 3.10 ) And (91.20 ± 2.17)%, respectively, which were significantly higher than those in the control group (82.61 ± 2.07)% and (85.36 ± 2.43)%, respectively (P <0.05). The incidence of adverse reactions in the study group was 5.41% less than that in the control group (24.32%, P <0.05). Conclusion The combination of montelukast sodium and budesonide in the treatment of bronchial asthma can achieve better clinical curative effect, which can not only improve the lung function of the patients, but also have higher safety and no obvious adverse reactions and is worth promoting .